Simulations Plus (NASDAQ:SLP) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• Technical move: Simulations Plus shares crossed above their 200‑day moving average of $15.87, trading as high as $17.32 and last at $15.88 on volume of 2,225,085 shares.
• Analyst sentiment is muted — the consensus rating is a Hold (3 Buy, 6 Hold, 1 Sell) with an average price target of $24.40 following recent downgrades and target cuts.
• Recent results showed an EPS and revenue beat (EPS $0.35 vs. $0.27; revenue $24.29M vs. $21.66M) but the company reported a negative net margin of 77.96% and a market cap of about $320.8M.

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $15.87 and traded as high as $17.32. Simulations Plus shares last traded at $15.88, with a volume of 2,225,085 shares traded.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Zacks Research downgraded Simulations Plus from a "strong-buy" rating to a "hold" rating in a report on Monday, February 2nd. TD Cowen reduced their target price on Simulations Plus from $19.00 to $16.00 and set a "hold" rating on the stock in a report on Friday, April 10th. Finally, Wall Street Zen downgraded Simulations Plus from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Three analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $24.40.

Simulations Plus Stock Performance

The stock has a fifty day simple moving average of $12.88 and a two-hundred day simple moving average of $15.87. The stock has a market cap of $320.78 million, a PE ratio of -5.07 and a beta of 1.28.

Simulations Plus (NASDAQ:SLP - Get Free Report) last posted its quarterly earnings data on Thursday, April 9th. The technology company reported $0.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.08. The company had revenue of $24.29 million for the quarter, compared to analyst estimates of $21.66 million. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. On average, equities analysts predict that Simulations Plus, Inc. will post 0.85 EPS for the current fiscal year.

Institutional Trading of Simulations Plus

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Tributary Capital Management LLC boosted its stake in shares of Simulations Plus by 214.7% during the 3rd quarter. Tributary Capital Management LLC now owns 1,136,980 shares of the technology company's stock valued at $17,134,000 after buying an additional 775,704 shares during the last quarter. Royce & Associates LP boosted its stake in Simulations Plus by 31.6% during the 3rd quarter. Royce & Associates LP now owns 348,758 shares of the technology company's stock valued at $5,256,000 after acquiring an additional 83,758 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in Simulations Plus during the 3rd quarter worth $1,810,000. JPMorgan Chase & Co. raised its stake in shares of Simulations Plus by 154.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 167,646 shares of the technology company's stock valued at $2,526,000 after purchasing an additional 101,822 shares in the last quarter. Finally, Herald Investment Management Ltd bought a new position in shares of Simulations Plus during the third quarter worth about $3,016,000. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc NASDAQ: SLP specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company's flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.